Crescent Biopharma Inc
Research Crescent Biopharma Inc (CBIO) on Bullrun: market cap USD 471.85M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCBIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 471.85M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 24.84M
- Free cash flow-USD 19.48M
Valuation Snapshot
latest market cap is USD 471.85M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 10.84M | USD 153.94K | -USD 72.45M | n/a | -10.99 | USD 213.19M | USD 1.64M | USD 203.01M |
| FY2024 | n/a | USD 37.88K | -USD 31.11M | n/a | -0.59 | USD 34.77M | n/a | -USD 15.48M |
| FY2023 | USD 10.00K | USD 36.90K | -USD 34.90M | n/a | -0.58 | USD 41.79M | n/a | USD 38.41M |
| FY2022 | USD 75.00K | -USD 46.69M | -USD 46.54M | n/a | -0.89 | USD 47.87M | n/a | USD 42.93M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 471.85M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 361.10M | n/a | n/a | n/a |
| 2024 | 2024-01-12 | n/a | n/a | 7.7% | 24 |
| 2023 | 2023-12-29 | n/a | n/a | 10.2% | 24 |
| 2022 | 2022-12-30 | n/a | n/a | 47.2% | 143 |
Dividend history
| Year | Dividends/share |
|---|---|
| FY2023 | 24 USD |
| FY2022 | 143 USD |
About Crescent Biopharma Inc
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Crescent Biopharma Inc's market cap?
Crescent Biopharma Inc's market capitalization is USD 471.85M.
What does Crescent Biopharma Inc do?
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.